| |
|
Product Name:
|
N2 NA Protein from Influenza Virus, A/shorebird/Delaware/127/1997 (H6N2), Recombinant from Baculovirus
|
|
Ownership statement:
|
This reagent is the tangible property of the U.S. Government.
|
|
Manufacturer:
|
NIH - Influenza Pandemic Preparedness in Asia Program
|
|
Material Provided:
|
Each vial contains 0.25 mL of purified recombinant N2 NA protein in 20 mM MOPS (pH 7.0) and 0.1% Tergitol. The concentration, expressed as μg/mL, is shown on the Certificate of Analysis.
|
|
Packing/Storage:
|
Purified recombinant N2 NA protein was packaged aseptically in cryovials. This product is provided on wet ice and should be stored at 2 to 8°C immediately upon arrival.
|
|
Functional Activity:
|
NR-657 is biologically active in a neuraminidase assay. NR-657 is specific to the N2 NA subtype of influenza virus as determined in serological neuraminidase inhibition (NI) assays. NR-657 demonstrates reactivity in NI and ELISA assays within the N2 NA subtype.
Applications: NI, ELISA, SDS-PAGE, Western blot, antiserum preparation (immunogen).
|
|
Disclaimers:
|
You are authorized to use this product for research use only. It is not intended for human use. Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org. While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate. This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/ or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products. |
|
Patents or other restrictions:
|
NR-657 is claimed in U.S. Patent Numbers 5,762,939 and 6,103,526, and the continuations, continuations-in-part, re-issues and foreign counterparts thereof. Commercial use also requires a license from Protein Sciences Corporation, Meriden, Connecticut. For information call 203-686-0800.
|
References:
|
1. Webby, R. J., P. R. Woolcock, S. L. Krauss, and R. G. Webster. “Reassortment and Interspecies Transmission of North American H6N2 Influenza Viruses.” Virology 295 (2002): 44–53. PubMed: 12033764.
2. Widjaja, L., et al. “Matrix Gene of Influenza A Viruses Isolated from Wild Aquatic Birds: Ecology and Emergence of Influenza A Viruses.” J. Virol. 78 (2004): 8771–8779. PubMed: 15280485.
3. Smith, G. E., et al. Method for Producing Influenza Hemagglutinin Multivalent Vaccines Using Baculovirus. MG-PMC, LLC, assignee. U.S. Patent 5,762,939. 09 Jun. 1998.
4. Smith, G. E., et al. Spodoptera frugiperda Single Cell Suspension Cell Line in Serum-Free Media, Methods of Producing and Using. Protein Sciences Corporation, assignee. U.S. Patent 6,103,526. 15 Aug. 2000.
|
|
Citation:
|
Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: N2 Neuraminidase (NA) Protein from Influenza Virus, A/shorebird/Delaware/127/1997 (H6N2), Recombinant from baculovirus, NR-657."
|
|
Biosafety Level:
|
1
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories (BMBL). Current Edition. Washington, DC: U.S. Government Printing Office.
|